A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
PHASE2WithdrawnINTERVENTIONAL
0
Timeline
Start Date
December 31, 2013
Primary Completion Date
January 31, 2017
Study Completion Date
February 28, 2017
Conditions
HIV
Interventions
DRUG
PRO 140
SC injection
DRUG
Placebo
SC injection
Trial Locations (1)
19102
Drexel University College of Medicine, Philadelphia
NCT01272258 - A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence | Biotech Hunter | Biotech Hunter